ARTICLE: Sulforaphane reduces hepatic glucose production and improves glucose control in patients with type 2 diabetes
AUTHORS: Annika S. Axelsson, Emily Tubbs, Brig Mecham, Shaji Chacko, Hannah A. Nenonen, Yunzhao Tang, Jed W. Fahey, Jonathan M. J. Derry, Claes B. Wollheim, Nils Wierup, Morey W. Haymond, Stephen H. Friend, Hindrik Mulder and Anders H. Rosengren
JOURNAL: Sci Transl Med. 2017 Jun 14;9(394). pii: eaah4477. doi: 10.1126/scitranslmed.aah4477.
A potentially useful approach for drug discovery is to connect gene expression profiles of disease-affected tissues ("disease signatures") to drug signatures, but it remains to be shown whether it can be used to identify clinically relevant treatment options. We analyzed coexpression networks and genetic data to identify a disease signature for type 2 diabetes in liver tissue. By interrogating a library of 3800 drug signatures, we identified sulforaphane as a compound that may reverse the disease signature. Sulforaphane suppressed glucose production from hepatic cells by nuclear translocation of nuclear factor erythroid 2-related factor 2 (NRF2) and decreased expression of key enzymes in gluconeogenesis. Moreover, sulforaphane reversed the disease signature in the livers from diabetic animals and attenuated exaggerated glucose production and glucose intolerance by a magnitude similar to that of metformin. Finally, sulforaphane, provided as concentrated broccoli sprout extract, reduced fasting blood glucose and glycated hemoglobin (HbA1c) in obese patients with dysregulated type 2 diabetes.
For a link to the full article, click here: http://stm.sciencemag.org/content/9/394/eaah4477.short
Link to abstract online: https://www.ncbi.nlm.nih.gov/pubmed/?term=Sulforaphane+reduces+hepatic+glucose+production+and+improves+glucose+control+in+patients+with+type+2+diabetes